- Home
- ARQT vs OPK Comparison
ARQT vs OPK Comparison
Compare ARQT & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- OPK
- Stock Information
- Founded
- ARQT 2016
- OPK 2007
- Country
- ARQT United States
- OPK United States
- Employees
- ARQT N/A
- OPK N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- OPK Biotechnology: Pharmaceutical Preparations
- Sector
- ARQT Health Care
- OPK Health Care
- Exchange
- ARQT Nasdaq
- OPK Nasdaq
- Market Cap
- ARQT 1.7B
- OPK N/A
- IPO Year
- ARQT 2020
- OPK 1995
- Fundamental
- Price
- ARQT $13.74
- OPK $1.32
- Analyst Decision
- ARQT Strong Buy
- OPK Buy
- Analyst Count
- ARQT 6
- OPK 4
- Target Price
- ARQT $18.80
- OPK $2.75
- AVG Volume (30 Days)
- ARQT 1.9M
- OPK 3.6M
- Earning Date
- ARQT 08-13-2025
- OPK 08-06-2025
- Dividend Yield
- ARQT N/A
- OPK N/A
- EPS Growth
- ARQT N/A
- OPK N/A
- EPS
- ARQT N/A
- OPK N/A
- Revenue
- ARQT $212,819,000.00
- OPK $689,408,000.00
- Revenue This Year
- ARQT $61.15
- OPK N/A
- Revenue Next Year
- ARQT $37.98
- OPK $7.80
- P/E Ratio
- ARQT N/A
- OPK N/A
- Revenue Growth
- ARQT 100.03
- OPK N/A
- 52 Week Low
- ARQT $7.86
- OPK $1.19
- 52 Week High
- ARQT $17.75
- OPK $2.04
- Technical
- Relative Strength Index (RSI)
- ARQT 56.81
- OPK 48.65
- Support Level
- ARQT $13.97
- OPK $1.26
- Resistance Level
- ARQT $14.69
- OPK $1.37
- Average True Range (ATR)
- ARQT 0.66
- OPK 0.04
- MACD
- ARQT 0.12
- OPK 0.00
- Stochastic Oscillator
- ARQT 78.87
- OPK 53.33
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.